Ernexa regains Nasdaq compliance, continues trading on exchange

CAMBRIDGE, Mass. - Ernexa Therapeutics (NASDAQ:ERNA) has regained compliance with Nasdaq’s minimum bid price requirement for continued listing, the company announced Wednesday. The biotech firm, currently valued at $14.1 million, has seen its shares decline over 56% year-to-date, according to InvestingPro data.

The cell therapy developer received formal notice from Nasdaq on July 1 confirming it had met the minimum bid price requirement under Listing Rule 5550(a)(2), allowing its stock to continue trading on the exchange.

"We remain laser-focused on advancing our programs toward the clinic, and we are on track to initiate our first clinical trial in early 2026," said Sanjeev Luther, President and CEO of Ernexa Therapeutics, in a press release statement.

Ernexa is developing engineered cell therapies for advanced cancer and autoimmune diseases. The company’s technology centers on transforming induced pluripotent stem cells into induced mesenchymal stem cells, creating what it describes as scalable, off-the-shelf treatments that don’t require patient-specific cell harvesting.

The company’s lead product candidate, ERNA-101, is being developed for ovarian cancer treatment, while its ERNA-102 program targets inflammation and autoimmune diseases.

Ernexa trades on the Nasdaq under the ticker symbol ERNA. The company’s compliance with listing requirements ensures its continued presence on the exchange, providing ongoing access to public market investors. According to InvestingPro, the company’s revenue grew by 365% in the last twelve months, though analysts don’t expect profitability this year. InvestingPro subscribers have access to 12 additional key insights about Ernexa’s financial health and market position.

In other recent news, Ernexa Therapeutics announced promising results from a study on its cell therapy for ovarian cancer, presented at the AACR Annual Meeting 2025. The research, led by Dr. Michael Andreeff, showed that engineered cells could significantly slow tumor growth and enhance the immune system’s response. Additionally, Ernexa completed the second closing of a securities purchase agreement, raising approximately $6 million in gross proceeds. This financing is aimed at strengthening the company’s balance sheet and advancing its pipeline of cell therapies. Ernexa also enacted a 1-for-15 reverse stock split to consolidate shares and maintain compliance with Nasdaq listing requirements. This move was approved by stockholders at the annual meeting. Furthermore, Ernexa changed its independent auditor to Haskell & White LLP, replacing Grant Thornton LLP, as part of a strategic shift in its financial oversight. The company noted no disagreements with the former auditor but identified a material weakness in internal control over financial reporting for 2023. These developments reflect Ernexa’s ongoing efforts to bolster its financial and operational strategies.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.